本文選題：巴塞羅那分期 + 香港分期　； 參考：《南京大學(xué)》2017年博士論文

【摘要】：肝細(xì)胞癌(hepatocellular carcinoma,HCC)是全球第五大惡性腫瘤,目前其發(fā)病率和死亡率仍高居不下。長(zhǎng)期以來(lái),形態(tài)各異的肝細(xì)胞癌與其生物學(xué)行為和預(yù)后的關(guān)系一直是學(xué)者們關(guān)注的熱點(diǎn)。目前認(rèn)為,HCC的大體形態(tài)與其分子病理學(xué)特征有著密切的聯(lián)系。2011年,美國(guó)Johns Hopkins大學(xué)醫(yī)學(xué)院的研究團(tuán)隊(duì)首先提出了呈浸潤(rùn)性生長(zhǎng)的HCC亞型(稱為浸潤(rùn)型肝細(xì)胞癌,infiltrative hepatocellular carcinoma,iHCC),其臨床特征主要包括:①多數(shù)合并乙型肝炎病毒(hepatitis B virus,HBV)感染;②具有與傳統(tǒng)HCC不同的影像學(xué)特點(diǎn),病灶邊界模糊不清,動(dòng)脈期強(qiáng)化不明顯,極易發(fā)生脈管侵犯等;③大多數(shù)有血清甲胎蛋白(alpha-fetoprotein,AFP)顯著升高。iHCC的概念一經(jīng)提出,立刻引起國(guó)際上臨床學(xué)者的重視。目前普遍認(rèn)為,iHCC呈浸潤(rùn)性生長(zhǎng)方式,腫瘤生長(zhǎng)迅速、浸潤(rùn)范圍廣,很快發(fā)生脈管癌栓、肝內(nèi)播散及全身轉(zhuǎn)移,是HCC中惡性程度最高的臨床亞型。但是,由于iHCC的高侵襲轉(zhuǎn)移特征,絕大多數(shù)病例被發(fā)現(xiàn)和確診時(shí)已到了晚期,失去了根治性治療的機(jī)會(huì)。因此,完整系統(tǒng)的臨床-影像-病理資料收集非常困難,限制了相關(guān)研究的深入。本研究團(tuán)隊(duì)自2013年開(kāi)始高度關(guān)注iHCC的相關(guān)臨床和基礎(chǔ)研究,經(jīng)過(guò)不斷積累獲得以下研究結(jié)果:①由于HBV感染是HCC主要發(fā)病因素,我國(guó)iHCC的發(fā)病率高于其他亞洲和歐美國(guó)家,我們統(tǒng)計(jì)的結(jié)果占HCC的30%,顯著高于歐美和日本的5～10%;②在不同大體分型的HCC中,iHCC的預(yù)后最差;③經(jīng)過(guò)大量臨床病例的觀察,我們?cè)趪?guó)內(nèi)外首先報(bào)道了在早-中期HCC中亦存在iHCC亞型。因此,本課題著重于iHCC的臨床和基礎(chǔ)研究。主要包括以下三個(gè)方面:①選擇適合浸潤(rùn)型肝細(xì)胞癌診療決策和預(yù)后分析的臨床分期;②通過(guò)分析手術(shù)切除iHCC病人的臨床特征及預(yù)后等信息,探索合適的治療策略;③通過(guò)全外顯子測(cè)序技術(shù),探索iHCC的關(guān)鍵特異性基因,探討其分子病理學(xué)特征。第一部分選擇適合浸潤(rùn)型肝細(xì)胞癌診療決策和預(yù)后分析的臨床分期目的:比較香港分期(Hong Kong Liver Cancer,HKLC)和巴塞羅那分期(Barcelona Clinic Liver Cancer,BCLC)在HBV相關(guān)性HCC病人中的預(yù)測(cè)預(yù)后能力。方法:668例HCC病人納入研究,應(yīng)用赤池信息量準(zhǔn)則(Akaike information criterion,AIC)、一致性指數(shù)(concordance-index,c-index)和 ROC 曲線下面積(area under the receiver operating characteristic curve,AUC)比較兩種分期的預(yù)后預(yù)測(cè)能力。通過(guò)單因素及多因素分析確定與生存相關(guān)的獨(dú)立危險(xiǎn)因素。結(jié)果:與生存相關(guān)的獨(dú)立危險(xiǎn)因素包括Child-Pugh評(píng)分、乳酸脫氫酶(lactate dehydrogenase,LDH)、白蛋白(albumin,ALB)、腫瘤部位、腫瘤數(shù)目、腫瘤大小和血管侵犯。HKLC分期的1、3、5年AUC分別為0.740,0.695和0.615,BCLC分期的1、3、5年AUC分別為0.622,0.569和0.548,提示HKLC分期的區(qū)分能力優(yōu)于BCLC分期。HKLC分期對(duì)生存的預(yù)測(cè)效能上亦優(yōu)于BCLC分期(HKLC 分期:AIC = 4709.480,c-index=0.805;BCLC 分期:AIC = 4852.708,c-index=0.717)。結(jié)論:HBV相關(guān)性HCC病人中,HKLC分期相比于BCLC分期來(lái)說(shuō)預(yù)測(cè)預(yù)后能力更強(qiáng),可能更適合以HBV感染為主要病因的中國(guó)HCC人群的預(yù)后分析以及治療決策。第二部分手術(shù)切除浸潤(rùn)型肝細(xì)胞癌的臨床特征分析目的:探討接受手術(shù)切除的浸潤(rùn)型肝細(xì)胞癌(infiltrative hepatocellular carcinoma,iHCC)病人的臨床特征及預(yù)后情況。方法:回顧性分析2003年1月至2012年12月在南京大學(xué)醫(yī)學(xué)院附屬鼓樓醫(yī)院肝膽胰外科行肝切除術(shù)的47名iHCC病人。通過(guò)單因素及多因素分析確定與生存及復(fù)發(fā)相關(guān)的獨(dú)立危險(xiǎn)因素。運(yùn)用卡方檢驗(yàn)、t檢驗(yàn)或Mann-Whitney 檢驗(yàn)分析微血管侵犯(microvascular invasion,MVI)與相關(guān)臨床指標(biāo)之間的關(guān)系。應(yīng)用Kaplan-Meier曲線進(jìn)行生存分析。結(jié)果:該組病人的中位生存時(shí)間為27.37個(gè)月,1年無(wú)復(fù)發(fā)生存率為61.7%。AFP并不是iHCC病人的特征性指標(biāo)。解剖性肝切除與較高的無(wú)復(fù)發(fā)生存期顯著相關(guān)(P=0.007),存在MVI的病人無(wú)復(fù)發(fā)生存期較低(P0.001)。血清LDH水平較高的病人總生存期(P=0.003)及無(wú)復(fù)發(fā)生存期(P=0.020)均較低。病人的MVI與血清谷草轉(zhuǎn)氨酶(aspartate aminotransferase,AST)、谷氨酰轉(zhuǎn)肽酶(gamma glutamyl transpeptidase,GGT)以及LDH水平有關(guān)。亞組分析提示在高水平LDH的病人中,低級(jí)別MVI的病人有較高的無(wú)復(fù)發(fā)生存期(P=0.019)。結(jié)論:iHCC病人具有較高的MVI發(fā)生率,對(duì)于早中期的病人來(lái)說(shuō),解剖性肝切除仍能使病人獲益。MVI分級(jí)可以用來(lái)區(qū)分出預(yù)后更差的一部分病人,尤其是具有較高血清LDH水平的病人。第三部分浸潤(rùn)型肝細(xì)胞癌分子病理學(xué)特點(diǎn)的探索目的:通過(guò)與單發(fā)結(jié)節(jié)型(single nodular,SN)HCC進(jìn)行比較,探索浸潤(rùn)型肝細(xì)胞癌(infiltrative hepatocellular carcinoma,iHCC)的特異性基因表達(dá)譜。方法:對(duì)6例腫瘤/相對(duì)正常的HCC組織樣本(3例iHCC、3例SN HCC)進(jìn)行全外顯子測(cè)序。隨后在30例HCC組織樣本(15例iHCC、15例SN HCC)中采用Sanger測(cè)序及RT-PCR技術(shù)進(jìn)行結(jié)果驗(yàn)證。結(jié)果:在對(duì)相應(yīng)組織樣本進(jìn)行全外顯子測(cè)序、Sanger測(cè)序及生物信息學(xué)分析后,結(jié)果提示iHCC與SN HCC展現(xiàn)出顯著不同的基因譜。尤其在iHCC中發(fā)現(xiàn)了一個(gè)較為典型的生長(zhǎng)因子受體酪氨酸激酶突變基因FGFR3,全外顯子測(cè)序發(fā)現(xiàn)了FGFR3的一個(gè)非同義突變位點(diǎn)c.G285T(p.Q95H),后續(xù)Sanger測(cè)序發(fā)現(xiàn)了另外五個(gè)突變位點(diǎn)(c.G938A:p.G313D,c.G1291A:p.A431T,c.C1355G:p.T452R,c.C1377T:p.L459L and c.A1445T:p.E482V)。免疫組化實(shí)驗(yàn)證實(shí)了 FGFR3 在 iHCC中存在較高的蛋白表達(dá)。結(jié)論:FGFR3可能是具有早期復(fù)發(fā)特點(diǎn)的iHCC的潛在候選癌基因及治療分子靶標(biāo)。
[Abstract]:Hepatocellular carcinoma (HCC) is the fifth largest malignant tumor in the world, and its morbidity and mortality still remain high. For a long time, the relationship between the different forms of hepatocellular carcinoma and its biological behavior and prognosis has been the focus of attention of scholars. At present, it is believed that the general morphology of HCC is closely related to its molecular pathological characteristics. In.2011, the research team of the medical school of Johns Hopkins University in the United States first proposed an infiltrative HCC subtype (called invasive hepatocellular carcinoma, infiltrative hepatocellular carcinoma, iHCC). Its clinical features mainly include: (1) most of the combination of hepatitis B virus (hepatitis B virus, HBV) infection; and (2) with traditional Chinese Medicine C has different imaging features, the boundary of the focus is unclear, the arterial phase is not obvious, and the vascular invasion is very easy to occur. (3) the concept of alpha-fetoprotein (AFP), which has a significant increase of.IHCC, is put forward immediately. Rapid, extensive infiltration, rapid vascular tumor thrombus, intrahepatic dissemination and whole body metastasis are the most malignant clinical subtypes in HCC. However, due to the high invasion and metastasis of iHCC, most cases have been found and confirmed at the late stage and lost the opportunity for radical treatment. The research team has been paying high attention to the related clinical and basic research of iHCC since 2013. The research team has accumulated the following results after continuous accumulation: (1) because HBV infection is the main factor of HCC, the incidence of iHCC in China is higher than that of other Asian and European countries, and our statistical results account for HC. The 30% of C was significantly higher than 5 to 10% in Europe and the United States and Japan; (2) the prognosis of iHCC was the worst in the HCC of different general classification. After a large number of clinical cases, we first reported the existence of iHCC subtype in the early and mid-term HCC. Therefore, this topic focuses on the clinical and basic research of iHCC, including the following aspects: (1) To select the clinical stages for the diagnosis and treatment of invasive hepatocellular carcinoma (HHC), and to explore the clinical features and prognosis of iHCC patients, explore the appropriate therapeutic strategies, and explore the key specific genes of iHCC through exon sequencing technology and explore its molecular pathological features. Clinical stages for the diagnosis and treatment of invasive hepatocellular carcinoma (Hong Kong Liver Cancer, HKLC) and Barcelona staging (Barcelona Clinic Liver Cancer, BCLC) in HBV associated HCC patients. Methods: 668 patients were included in the study. Ation criterion, AIC), the conformance index (concordance-index, c-index) and the area under the ROC curve (area under the receiver operating characteristic) compared the predictive ability of the two stages. Independent risk factors associated with survival were determined by single factor and multifactor analysis. Results: independent risk associated with survival Factors including Child-Pugh score, lactate dehydrogenase (LDH), albumin (albumin, ALB), tumor site, tumor number, tumor size, and vascular invasion.HKLC stages were 0.740,0.695 and 0.615, respectively, and 1,3,5 years of BCLC staging were different and 0.548. .HKLC staging was also superior to BCLC staging for survival (HKLC staging: AIC = 4709.480, c-index=0.805; BCLC staging: AIC = 4852.708, c-index=0.717). Conclusion: in HBV associated HCC patients, HKLC staging is more likely to predict prognosis than BCLC stages, and may be more suitable for the Chinese population with the main cause of infection. Prognostic analysis and treatment decisions. Clinical features of second parts of surgical excision of infiltrating hepatocellular carcinoma (infiltrative hepatocellular carcinoma, iHCC): the clinical features and prognosis of patients undergoing surgical excision (carcinoma, iHCC). Methods: retrospective analysis from January 2003 to December 2012 at the Nanjing University medicine 47 iHCC patients who underwent hepatectomy of hepatobiliary and pancreatic surgery affiliated to the College Affiliated Drum hospital. Independent risk factors associated with survival and recurrence were determined by single factor and multifactor analysis. The relationship between microvascular invasion (microvascular invasion, MVI) and related clinical indicators was analyzed by chi square test, t test or Mann-Whitney test. The application of K Survival analysis of the aplan-Meier curve. Results: the median survival time of the patients was 27.37 months, and the 1 year non recurrent survival rate was 61.7%.AFP, not the characteristic index of the iHCC patients. The anatomical hepatectomy was significantly correlated with the higher recurrence free survival (P=0.007), and the non recurrent survival time in the patients with MVI was lower (P0.001). The serum LDH level was low (P0.001). Higher patient total survival (P=0.003) and non recurrent survival (P=0.020) were lower. The patient's MVI was associated with serum aspartate aminotransferase (AST), glutamyl transpeptidase (gamma glutamyl transpeptidase, GGT), and LDH levels. Subgroup analysis suggested that patients with low level LDH were higher in the high level LDH patients. No recurrence of survival (P=0.019). Conclusion: iHCC patients have a high incidence of MVI. For patients with early and middle stages, anatomical hepatectomy can still benefit the patients with.MVI classification, which can be used to distinguish some patients with worse prognosis, especially in patients with higher serum LDH levels. Third part of the molecular pathology of infiltrating hepatocellular carcinoma. Objective: To explore the specific gene expression profiles of invasive hepatocellular carcinoma (infiltrative hepatocellular carcinoma, iHCC) by comparing with single nodular (SN) HCC. Methods: 6 cases of tumor / relatively normal HCC tissue samples (3 iHCC, 3 SN HCC) were sequenced in 30 cases. The fabric samples (15 iHCC, 15 SN HCC) were verified by Sanger sequencing and RT-PCR technology. Results: after the whole exon sequencing, Sanger sequencing and bioinformatics analysis of the corresponding tissue samples, the results showed that the iHCC and SN HCC showed significant different gene spectrum. In particular, a more typical growth factor was found in iHCC. Subreceptor tyrosine kinase mutation gene FGFR3, exon sequencing found a non synonymous mutation site of FGFR3 c.G285T (p.Q95H), followed by Sanger sequencing found five other mutation sites (c.G938A:p.G313D, c.G1291A:p.A431T, c.C1355G:p.T452R, c.C1377T:p.L459L and c.A1445T:p.E482V). Immunohistochemistry test confirmed FGFR3 in Conclusion: FGFR3 may be a potential candidate gene and therapeutic molecular target for iHCC with early recurrence characteristics. Conclusion: iHCC is a potential candidate gene for early relapse.

【學(xué)位授予單位】：南京大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 徐衛(wèi)東,張春平,王桂榮;肝細(xì)胞癌的變化模式[J];國(guó)外醫(yī)學(xué)(內(nèi)科學(xué)分冊(cè));2000年10期

2 ;早期發(fā)現(xiàn)肝細(xì)胞癌可增加治療機(jī)會(huì)[J];河南醫(yī)學(xué)研究;2000年02期

3 Schafer DF,潘朝法,李蘇云;肝細(xì)胞癌[J];第四軍醫(yī)大學(xué)吉林軍醫(yī)學(xué)院學(xué)報(bào);2000年01期

4 中沼安二,林淑蘭,姚楨;有關(guān)小肝細(xì)胞癌病理學(xué)的最新認(rèn)識(shí)[J];日本醫(yī)學(xué)介紹;2000年05期

5 靜雨;;美國(guó)肝細(xì)胞癌發(fā)病率增高[J];國(guó)外醫(yī)學(xué)情報(bào);2000年01期

6 張玉勛;;肝細(xì)胞癌的非手術(shù)治療[J];國(guó)外醫(yī)學(xué)情報(bào);2000年05期

7 徐宏勇,李開(kāi)宗,付由池,竇科峰,李景夢(mèng),何揚(yáng)舉;bcl-x,bax基因表達(dá)與肝細(xì)胞癌臨床病理特征的關(guān)系[J];第四軍醫(yī)大學(xué)學(xué)報(bào);2001年14期

8 蔡端;多中心源肝細(xì)胞癌的特征:與肝內(nèi)轉(zhuǎn)移的比較[J];國(guó)外醫(yī)學(xué).外科學(xué)分冊(cè);2002年02期

9 張春平;與白介素-18水平升高有關(guān)的肝細(xì)胞癌自發(fā)性消退[J];國(guó)外醫(yī)學(xué)(內(nèi)科學(xué)分冊(cè));2003年03期

10 薛海鷗,岳莉;兒童肝細(xì)胞癌1例報(bào)告[J];錦州醫(yī)學(xué)院學(xué)報(bào);2003年04期

相關(guān)會(huì)議論文 前10條

1 卞讀軍;;肝細(xì)胞癌經(jīng)導(dǎo)管動(dòng)脈化療栓塞前后磁共振波譜研究[A];2009中華醫(yī)學(xué)會(huì)影像技術(shù)分會(huì)第十七次全國(guó)學(xué)術(shù)大會(huì)論文集[C];2009年

2 賈建偉;趙潔;;肝細(xì)胞癌領(lǐng)域研究現(xiàn)狀與進(jìn)展[A];中醫(yī)藥防治感染病之研究（九）——第九次全國(guó)中醫(yī)藥防治感染病學(xué)術(shù)交流大會(huì)論文集[C];2009年

3 陳孝平;;肝細(xì)胞癌外科治療進(jìn)展[A];湖北省第21屆腫瘤學(xué)術(shù)大會(huì)論文匯編[C];2011年

4 張杰;劉軍建;韓云;張寧;芮靜安;金城;周柔麗;;用熒光差異顯示法篩選肝細(xì)胞癌相關(guān)新基因[A];2000全國(guó)腫瘤學(xué)術(shù)大會(huì)論文集[C];2000年

5 馮仕庭;李子平;譚國(guó)勝;孫燦輝;彭振鵬;;中晚期肝細(xì)胞癌的多層螺旋CT血管造影表現(xiàn)及臨床應(yīng)用[A];中華醫(yī)學(xué)會(huì)第十三屆全國(guó)放射學(xué)大會(huì)論文匯編（下冊(cè)）[C];2006年

6 張法標(biāo);方哲平;王義;董輝;叢文銘;;上皮鈣粘素和β-連接素在兒童肝細(xì)胞癌中的表達(dá)及其臨床意義[A];2007年浙江省外科學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2007年

7 陳鐘杰;;螺旋CT診斷原發(fā)型肝細(xì)胞癌28例[A];2008年浙江省放射學(xué)年會(huì)論文匯編[C];2008年

8 賈克東;;肝細(xì)胞癌的診斷進(jìn)展及治療現(xiàn)狀[A];全國(guó)中西醫(yī)結(jié)合肝病新進(jìn)展講習(xí)班、江西省第二次中西醫(yī)結(jié)合肝病學(xué)術(shù)會(huì)議資料匯編[C];2010年

9 李秋萍;龍順欽;楊小兵;鄧宏;蔡姣芝;潘宗奇;河文峰;周宇姝;歐陽(yáng)育樹(shù);廖桂雅;吳萬(wàn)垠;;癌服靈治療晚期肝細(xì)胞癌的臨床研究[A];2012·中國(guó)醫(yī)師協(xié)會(huì)中西醫(yī)結(jié)合醫(yī)師大會(huì)第三次會(huì)議論文集[C];2012年

10 朱明華;祝峙;劉曉紅;林靜;曲建慧;陳穎;曹曉哲;王力;倪燦榮;;乙型肝炎病毒感染與肝細(xì)胞癌發(fā)生關(guān)系的分子病理學(xué)研究[A];中華醫(yī)學(xué)會(huì)病理學(xué)分會(huì)2009年學(xué)術(shù)年會(huì)論文匯編[C];2009年

相關(guān)重要報(bào)紙文章 前10條

1 中國(guó)抗癌協(xié)會(huì)臨床腫瘤學(xué)協(xié)作專業(yè)委員會(huì)主任委員 秦叔逵;治療肝細(xì)胞癌 別只盯著靶向藥[N];健康報(bào);2013年

2 記者 王丹 管九蘋;肝細(xì)胞癌標(biāo)志物研究獲新進(jìn)展[N];健康報(bào);2013年

3 吳一福;四軍醫(yī)大唐都醫(yī)院發(fā)現(xiàn)硒蛋白P與肝細(xì)胞癌發(fā)生有關(guān)[N];中國(guó)醫(yī)藥報(bào);2007年

4 黎彬;肝癌研究重要進(jìn)展——預(yù)測(cè)肝癌轉(zhuǎn)移成為可能[N];中國(guó)醫(yī)藥報(bào);2004年

5 錢文彩;α2δ1陽(yáng)性細(xì)胞為新的肝細(xì)胞癌干細(xì)胞[N];中國(guó)醫(yī)藥報(bào);2013年

6 新美;基礎(chǔ)研究進(jìn)展推動(dòng)肝臟病學(xué)進(jìn)步[N];中國(guó)醫(yī)藥報(bào);2008年

7 周金蓮;MIB-1和bcl-2表達(dá)預(yù)測(cè)肝癌發(fā)生[N];中國(guó)醫(yī)藥報(bào);2004年

8 張金山;要靈活運(yùn)用影像學(xué)提供的方法和手段[N];中國(guó)高新技術(shù)產(chǎn)業(yè)導(dǎo)報(bào);2001年

9 李杰;不能手術(shù)切除肝細(xì)胞癌的治療[N];科技日?qǐng)?bào);2006年

10 ;修復(fù)肝細(xì)胞 改善肝功能[N];人民日?qǐng)?bào)海外版;2006年

相關(guān)博士學(xué)位論文 前10條

1 白蘭;乙肝病毒捕獲細(xì)胞因子和信號(hào)級(jí)聯(lián)以逃避宿主免疫并維持持續(xù)感染[D];武漢大學(xué);2014年

2 何洪衛(wèi);肝細(xì)胞癌內(nèi)γδT細(xì)胞浸潤(rùn)減少及功能缺陷的機(jī)制研究[D];復(fù)旦大學(xué);2014年

3 蔡曉燕;淋巴細(xì)胞在肝細(xì)胞癌和癌旁組織中的差異性表達(dá)研究[D];復(fù)旦大學(xué);2014年

4 向?qū)?細(xì)胞周期因子FoxM1促進(jìn)肝臟再殖的研究[D];第二軍醫(yī)大學(xué);2015年

5 康富標(biāo);共刺激分子B7-H3在肝細(xì)胞癌的表達(dá)及相關(guān)機(jī)制研究[D];中國(guó)人民解放軍醫(yī)學(xué)院;2015年

6 楊純;Gankyrin正反饋調(diào)控Nrf2在肝細(xì)胞癌中發(fā)揮抗氧化作用[D];第二軍醫(yī)大學(xué);2015年

7 高霞;PNPLA3基因單核苷酸多態(tài)性及基因表達(dá)與乙肝病毒感染易感性及乙肝相關(guān)肝細(xì)胞癌的關(guān)聯(lián)性研究[D];河北醫(yī)科大學(xué);2016年

8 彭晨星;microRNA結(jié)合位點(diǎn)單核苷酸多態(tài)性對(duì)肝細(xì)胞癌預(yù)后影響的相關(guān)性研究[D];河北醫(yī)科大學(xué);2016年

9 田偉;γδT細(xì)胞免疫治療肝細(xì)胞癌的實(shí)驗(yàn)研究[D];山西醫(yī)科大學(xué);2016年

10 葉甲舟;RBM8A與肝細(xì)胞癌的相關(guān)性及對(duì)肝細(xì)胞癌增殖及凋亡生物學(xué)特性的影響[D];廣西醫(yī)科大學(xué);2016年

相關(guān)碩士學(xué)位論文 前10條

1 王飛;CDH17調(diào)控肝細(xì)胞癌的生物學(xué)機(jī)制的研究[D];福建醫(yī)科大學(xué);2015年

2 陳中博;咖啡攝入與肝細(xì)胞癌發(fā)病風(fēng)險(xiǎn)的Meta分析[D];河北醫(yī)科大學(xué);2015年

3 張華鵬;核受體輔激活蛋白5在肝細(xì)胞癌組織中的表達(dá)及其臨床意義[D];鄭州大學(xué);2015年

4 郭慧敏;血清sCD25測(cè)定在肝細(xì)胞癌診斷中的意義[D];鄭州大學(xué);2015年

5 凌青霞;雙氧化酶1（Duox1）在肝細(xì)胞癌中的表達(dá)調(diào)控及作用研究[D];復(fù)旦大學(xué);2014年

6 李會(huì)芬;血清Talin-1在肝細(xì)胞癌診斷中的作用[D];鄭州大學(xué);2015年

7 蒙錦瑩;血管生長(zhǎng)相關(guān)因子的血清濃度與肝細(xì)胞癌預(yù)后的相關(guān)性研究[D];蘭州大學(xué);2015年

8 戰(zhàn)勇;肝細(xì)胞癌術(shù)前造影參數(shù)與生物學(xué)表現(xiàn)相關(guān)性及術(shù)后復(fù)發(fā)相關(guān)因素討論[D];中國(guó)人民解放軍醫(yī)學(xué)院;2015年

9 姚樂(lè);microRNA-32在肝細(xì)胞癌中的表達(dá)及其臨床預(yù)后意義[D];河北醫(yī)科大學(xué);2015年

10 吳華;MACC1在肝細(xì)胞癌中的表達(dá)與臨床意義[D];安徽醫(yī)科大學(xué);2015年

，

本文編號(hào)：1825069